A cognitive fMRI study of non-manifesting LRRK2 and GBA carriers
Objective: To assess the cognitive profile of non-manifesting carriers of GBA and LRRK2 mutations using two fMRI tasks: a Stroop interference and N-Back working memory…Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3beta activity
Objective: To identify disease-modifying therapy for LRRK2-G2019S parkinsonism. Background: Leucine-rich repeat kinase 2 (LRRK2) is the most common genetic cause of Parkinson's disease (PD) without…Lack of association between LRRK2 G2385R and cognitive dysfunction in Korean patients with idiopathic Parkinson’s disease
Objective: We investigated whether the G2385R polymorphism in LRRK2, a risk allele for the development of idiopathic Parkinson's disease (IPD) in East Asians, is associated…Reduced thalamo-cortical functional connectivity in asymptomatic LRRK2 mutation carriers
Objective: To characterize MRI functional patterns during resting state in asymptomatic LRRK2 mutation carriers. Background: Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are…Inflammatory profile discriminates clinical subtypes in LRRK2-associated PD
Objective: To evaluate whether inflammatory processes in PD patients with mutations in the LRRK2 gene (PD-LRRK2) are associated with modification of clinical features and disease…The role of non-steroidal anti-inflammatory use in symptomatic and asymptomatic LRRK2 G2019S mutation carriers
Objective: The purpose of the current study is to determine if non-steroidal anti-inflammatory drugs (NSAIDs) reduce the risk of Parkinson's disease (PD) among LRRK2 G2019S…
- « Previous Page
- 1
- …
- 14
- 15
- 16